Workshop on Combination Therapy for Cancer: Opportunities and Obstacles for Future Development
July 29, 2006
Doubletree Hotel
Rockville, MD
Note: The slides provided by the presenters are accessible for viewing and printing only. Please click on the 
icon to view the individual presentations.
Leadership Perspectives on Biologic Combinations
Perspectives from NCI
Robert Wiltrout, PhD - National Cancer Institute
Perspectives from FDA
Raj Puri, MD, PhD - Food and Drug Administration
Perspective from EORTC
Alexander Eggermont, MD, PhD - Erasmus University Medical Center
Opportunities and Obstacles to Developing Novel Biologic Combinations
Academic Perspective
Michael Atkins, MD - Beth Israel Deaconess Medical Center
Industry Perspective
Geoffrey Nichol, MD, MBA - Medarex, Inc.
Regulatory Perspective
Steven Hirschfeld, MD, PhD - Food and Drug Administration
State of the Art
State of the Art 1: Combination Immunotherapy
Lead Presenter: Thomas Gajewski, MD, PhD - University of Chicago
Panel:
James Allison, PhD - Memorial Sloan-Kettering Cancer Center
Drew Pardoll, Md, PhD - Johns Hopkins University School of Medicine
Jon Wigginton, MD - Merck
State of the Art 2: Combination Immune-Antiangiogenic Therapy
Lead Presenter:
Kim Margolin, MD -
City of HopePanel:
George Coukos, MD, PhD -
University of PennsylvaniaRalph Reisfeld, PhD -
Scripps Research InstituteRobert Wiltrout, PhD - National Cancer Institute
State of the Art 3: Combination Immune Therapy-Modulator of Apoptosis
Lead Presenter: Craig Slingluff, Jr., MD - University of Virginia
Panel:
James Finke, PhD - Cleveland Clinic Foundation
Crystal Mackall, MD - National Cancer Institute
James Mier, MD - Beth Israel Deaconess Medical Center
State of the Art 4: Combination Immune Therapy-Chemotherapy
Lead Presenter: Elizabeth Jaffee, MD - Johns Hopkins University
Panel:
Jared Gollob, MD - Duke University
John Kirkwood, MD -
University of Pittsburgh Cancer InstituteJames Yang, MD - National Cancer Institute
Facilitated Concurrent Breakout Sessions
Breakout 1: Scientific Barriers to Investigation of Novel Combinations
Leaders:
Bernard Fox, PhD - Earle A. Chiles Research Institute
Michael T. Lotze, MD - University of Pittsburgh
William Murphy, PhD - University of Nevada School of Medicine
Nicholas Restifo, MD - National Cancer Institute
Breakout 2: Clinical Trial Design and Development of Combinations
Leaders:
Rachel Humphrey, MD - Bristol Myers-Squibb Company
Carl H. June, MD - University of Pennsylvania
Ulrich Keilholz, MD - Charité, CBF, Berlin
Walter Urba, MD, PhD - Earle A. Chiles Research Institute
Breakout 3: Regulatory Issues and the Development of Combinations
Leaders:
Jeffrey Weber, MD, PhD - Norris Cancer Center
Ashok Batra, MD - Food and Drug Administration/CBER
Alexander Eggermont, MD, PhD - Erasmus University Medical Center
David Ross, MD - Food and Drug Administration/CDER
Breakout 4: Intellectual Property Barriers to the Development of Combinations
Leaders:
Kathleen Sybert, PhD, Esq. - Clinical Technology Transfer Group
Edward Berg - Bristol Myers-Squibb Company
Breakout Session Discussion Reports
Breakout 1: Bernard Fox, PhD -
Earle A. Chiles Research InstituteBreakout 2: Rachel Humphrey, MD -
Bristol Myers-Squibb CompanyBreakout 3: Jeffrey Weber, MD, PhD -
Norris Cancer CenterBreakout 4: Edward Berg -
Bristol Myers-Squibb Company
Closing Comments
Steven Rosenberg, MD, PhD - National Cancer Institute
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

